Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1918 1
1921 1
1925 1
1927 1
1929 2
1935 1
1937 1
1946 2
1950 1
1951 3
1953 2
1954 3
1955 2
1956 2
1957 6
1958 2
1959 3
1960 4
1961 2
1962 3
1963 1
1964 4
1965 2
1966 2
1967 6
1968 12
1969 4
1970 3
1971 9
1972 9
1973 14
1974 16
1975 22
1976 18
1977 18
1978 6
1979 12
1980 13
1981 16
1982 8
1983 10
1984 12
1985 11
1986 7
1987 18
1988 18
1989 21
1990 17
1991 16
1992 17
1993 17
1994 14
1995 9
1996 15
1997 11
1998 13
1999 9
2000 10
2001 8
2002 11
2003 19
2004 13
2005 27
2006 25
2007 24
2008 24
2009 30
2010 24
2011 23
2012 28
2013 27
2014 31
2015 27
2016 38
2017 39
2018 29
2019 30
2020 36
2021 41
2022 41
2023 45
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,088 results

Results by year

Filters applied: . Clear all
Page 1
Targeting RAGE Signaling in Inflammatory Disease.
Hudson BI, Lippman ME. Hudson BI, et al. Annu Rev Med. 2018 Jan 29;69:349-364. doi: 10.1146/annurev-med-041316-085215. Epub 2017 Nov 6. Annu Rev Med. 2018. PMID: 29106804 Review.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schönherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB. Subbiah V, et al. Among authors: hudson bm. Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475. Cancer Discov. 2023. PMID: 37270847 Free PMC article.
Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials.
Whitley J, Zwolinski C, Denis C, Maughan M, Hayles L, Clarke D, Snare M, Liao H, Chiou S, Marmura T, Zoeller H, Hudson B, Peart J, Johnson M, Karlsson A, Wang Y, Nagle C, Harris C, Tonkin D, Fraser S, Capiz L, Zeno CL, Meli Y, Martik D, Ozaki DA, Caparoni A, Dickens JE, Weissman D, Saunders KO, Haynes BF, Sempowski GD, Denny TN, Johnson MR. Whitley J, et al. Among authors: hudson b. Transl Res. 2022 Apr;242:38-55. doi: 10.1016/j.trsl.2021.11.009. Epub 2021 Dec 4. Transl Res. 2022. PMID: 34871810 Free PMC article. Review.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Among authors: hudson bm. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, Fields PA, Hu S, Denmeade SR, Pienta KJ, Pavlovich CP, Ross AE, Drake CG, Pardoll DM, Antonarakis ES. Shenderov E, et al. Among authors: hudson b. Nat Med. 2023 Apr;29(4):888-897. doi: 10.1038/s41591-023-02284-w. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012549 Free PMC article. Clinical Trial.
Progress in Glioma Stem Cell Research.
Ramar V, Guo S, Hudson B, Liu M. Ramar V, et al. Among authors: hudson b. Cancers (Basel). 2023 Dec 24;16(1):102. doi: 10.3390/cancers16010102. Cancers (Basel). 2023. PMID: 38201528 Free PMC article. Review.
FFA4/GPR120: Pharmacology and Therapeutic Opportunities.
Milligan G, Alvarez-Curto E, Hudson BD, Prihandoko R, Tobin AB. Milligan G, et al. Among authors: hudson bd. Trends Pharmacol Sci. 2017 Sep;38(9):809-821. doi: 10.1016/j.tips.2017.06.006. Epub 2017 Jul 19. Trends Pharmacol Sci. 2017. PMID: 28734639 Free PMC article. Review.
A Randomized Trial of Nafamostat for Covid-19.
Morpeth SC, Venkatesh B, Totterdell JA, McPhee GM, Mahar RK, Jones M, Bandara M, Barina LA, Basnet BK, Bowen AC, Burke AJ, Cochrane B, Denholm JT, Dhungana A, Dore GJ, Dotel R, Duffy E, Dummer J, Foo H, Gilbey TL, Hammond NE, Hudson BJ, Jha V, Jevaji PR, John O, Joshi R, Kang G, Kaur B, Kim S, Das SK, Lau JSY, Littleford R, Marsh JA, Marschner IC, Matthews G, Maze MJ, McArthur CJ, McFadyen JD, McMahon JH, McQuilten ZK, Molton J, Mora JM, Mudaliar V, Nguyen V, O'Sullivan MVN, Pant S, Park JE, Paterson DL, Price DJ, Raymond N, Rees MA, Robinson JO, Rogers BA, Ryu WS, Sasadeusz J, Shum O, Snelling TL, Sommerville C, Trask N, Lewin SR, Hills TE, Davis JS, Roberts JA, Tong SYC. Morpeth SC, et al. Among authors: hudson bj. NEJM Evid. 2023 Nov;2(11):EVIDoa2300132. doi: 10.1056/EVIDoa2300132. Epub 2023 Oct 18. NEJM Evid. 2023. PMID: 38320527 Clinical Trial.
Mammalian collagen IV.
Khoshnoodi J, Pedchenko V, Hudson BG. Khoshnoodi J, et al. Among authors: hudson bg. Microsc Res Tech. 2008 May;71(5):357-70. doi: 10.1002/jemt.20564. Microsc Res Tech. 2008. PMID: 18219669 Free PMC article. Review.
1,088 results